Focus: Guerbet is a specialized pharmaceutical company focused on contrast agents and injectors for diagnostic imaging across oncology, nephrology, cardiovascular, gastroenterology, and neurology. As a publicly traded company headquartered in France, it occupies a niche but essential position in the medical imaging supply chain.
Profile data last refreshed 4d ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Guerbet to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key X-ray contrast agent with broad clinical use in high-risk patient populations.
Help build intelligence for Guerbet
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Guerbet's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
MRI contrast agent available in standard and plastic container formulations; approaching generic competition.
Legacy iodinated contrast portfolio with multiple strength variants; foundational products now facing exclusivity erosion.
Diatrizoate-based contrast agent in advanced genericization phase.
Additional contrast agent approaching loss of exclusivity.
15 discontinued, 8 duplicate formulations not shown
Guerbet announces an important milestone achievement in the "Vascular Embolization" indication for Lipiodol® Ultra Fluid (Iodinated ethyl esters of fatty acids of poppy seed oil) - The Malaysian Reserve
Guerbet announces an important milestone achievement in the "Vascular Embolization" indication for Lipiodol® Ultra Fluid (Iodinated ethyl esters of fatty acids of poppy seed oil) The Malaysian Reserve
Raleigh factory violations drag down French firm's revenue - The Business Journals
Raleigh factory violations drag down French firm's revenue The Business Journals
GUERBET : 2025 full-year results. - GlobeNewswire
GUERBET : 2025 full-year results. GlobeNewswire
GUERBET : 2025 full-year results. - GlobeNewswire
GUERBET : 2025 full-year results. GlobeNewswire
GUERBET : Change in Guerbet’s Board of Directors. - GlobeNewswire
GUERBET : Change in Guerbet’s Board of Directors. GlobeNewswire
New indication in pediatric patients, including term neonates for Guerbet's half-dose GBCA, Elucirem™ (Gadopiclenol) Injection - PR Newswire
New indication in pediatric patients, including term neonates for Guerbet's half-dose GBCA, Elucirem™ (Gadopiclenol) Injection PR Newswire
Showing 6 of 7 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
Understanding the challenges to implementing AI solutions in radiology departments and how to overcome them: A comprehensive review endorsed by the French College of Radiologists (CERF) and the French Society of Radiology (SFR).
A Deep Learning Algorithm for Liver Metastasis Detection at Contrast-enhanced Abdominal CT in Patients with Colorectal Cancer: A Comparative Study with Radiologists.
Showing 5 of 10 publications